Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial
Authors:
Open Access
- 6 October 2022
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 40 (12) , 1207-1220
Abstract
Background and Objective Most guidelines in the UK, Europe and North America do not recommend organised population-wide screening for prostate cancer. Prostate-specific antigen-based screening can reduce prostate cancer-specific mortality, but there are concerns about overdiagnosis, overtreatment and economic value. The aim was therefore to assess the cost effectiveness of eight potential screening strategies in the UK. Methods We used a cost-utility analysis with an individual-based simulation model. The model was calibrated to data from the 10-year follow-up of the Cluster Randomised Trial of PSA Testing for Prostate Cancer (CAP). Treatment effects were modelled using data from the Prostate Testing for Cancer and Treatment (ProtecT) trial. The participants were a hypothetical population of 10 million men in the UK followed from age 30 years to death. The strategies were: no screening; five age-based screening strategies; adaptive screening, where men with an initial prostate-specific antigen level of < 1.5 ng/mL are screened every 6 years and those above this level are screened every 4 years; and two polygenic risk-stratified screening strategies. We assumed the use of pre-biopsy multi-parametric magnetic resonance imaging for men with prostate-specific antigen ≥ 3 ng/mL and combined transrectal ultrasound-guided and targeted biopsies. The main outcome measures were projected lifetime costs and quality-adjusted life-years from a National Health Service perspective. Results All screening strategies increased costs compared with no screening, with the majority also increasing quality-adjusted life-years. At willingness-to-pay thresholds of £20,000 or £30,000 per quality-adjusted life-year gained, a once-off screening at age 50 years was optimal, although this was sensitive to the utility estimates used. Although the polygenic risk-stratified screening strategies were not on the cost-effectiveness frontier, there was evidence to suggest that they were less cost ineffective than the alternative age-based strategies. Conclusions Of the prostate-specific antigen-based strategies compared, only a once-off screening at age 50 years was potentially cost effective at current UK willingness-to-pay thresholds. An additional follow-up of CAP to 15 years may reduce uncertainty about the cost effectiveness of the screening strategies.Keywords
Funding Information
- Cancer Research UK (C11043/A4286, C18281/A8145, C18281/A11326, C18281/A15064, C18281/A24432)
This publication has 52 references indexed in Scilit:
- Screening for Prostate Cancer: Results of the Rotterdam Section of the European Randomized Study of Screening for Prostate CancerEuropean Urology, 2013
- Prostate-Specific Antigen Test for Prostate Cancer Screening: American Society of Clinical Oncology Provisional Clinical OpinionJournal of Oncology Practice, 2012
- Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT studyBMJ, 2012
- An Epidemiological Reappraisal of the Familial Aggregation of Prostate Cancer: A Meta-AnalysisPLOS ONE, 2011
- How Does Early Detection by Screening Affect Disease Progression?Medical Decision Making, 2011
- Calibrating disease progression models using population data: a critical precursor to policy development in cancer controlBiostatistics, 2010
- American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010CA: A Cancer Journal for Clinicians, 2010
- A web-based tool for adjusting costs to a specific target currency and price yearEvidence & Policy, 2010
- Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling ApproachMedical Decision Making, 2008
- Construction of the Patient-Oriented Prostate Utility Scale (PORPUS)Journal of Clinical Epidemiology, 2000